MicroRNA-17/20a inhibits glucocorticoid-induced osteoclast differentiation and function through targeting RANKL expression in osteoblast cells

Bone

Volumn 68, Issue , 2014, Pages 67-75

  Shi, Changgui ^b   Qi, Jin ^a   Huang, Ping ^a   Jiang, Min ^a   Zhou, Qi ^a   Zhou, Hanbing ^a   Kang, Hui ^a   Qian, Niandong ^a   Yang, Qiumeng ^a   Guo, Lei ^a   Deng, Lianfu ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Glucocorticoids; MicroRNA 17 20a; Osteoclasts; Osteoporosis; RANKL

Indexed keywords

DEXAMETHASONE; MESSENGER RNA; MICRORNA; MICRORNA 17; MICRORNA 20A; OSTEOCLAST DIFFERENTIATION FACTOR; UNCLASSIFIED DRUG; GLUCOCORTICOID; MIRN17 MICRORNA, MOUSE; MIRN20 MICRORNA, MOUSE;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; COCULTURE; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; INHIBITION KINETICS; LUCIFERASE ASSAY; MOUSE; NEWBORN; NONHUMAN; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN EXPRESSION; RANKL GENE; UPREGULATION; WESTERN BLOTTING; ANIMAL; BONE DEVELOPMENT; C57BL MOUSE; CELL DIFFERENTIATION; CELL LINE; CYTOLOGY; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; OSTEOCLAST; PATHOLOGY;

ANIMALS; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINE; COCULTURE TECHNIQUES; DEXAMETHASONE; DOWN-REGULATION; GLUCOCORTICOIDS; HEK293 CELLS; HUMANS; MICE, INBRED C57BL; MICRORNAS; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; RANK LIGAND;

EID: 84906705068     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.08.004     Document Type: Article

References (39)

1. Del R.I., Battafarano D.F., Restrepo J.F., Erikson J.M., Escalante A. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol 2014, 66:264-272.
2. Jonasson S., Hedenstierna G., Hjoberg J. Concomitant administration of nitric oxide and glucocorticoids improves protection against bronchoconstriction in a murine model of asthma. J Appl Physiol 2010, 109:521-531.
3. Tait A.S., Butts C.L., Sternberg E.M. The role of glucocorticoids and progestins in inflammatory, autoimmune, and infectious disease. J Leukoc Biol 2008, 84:924-931.
4. Capozzi A., Casa S.D., Altieri B., Pontecorvi A. Chronic low-dose glucocorticoid inhalatory therapy as a cause of bone loss in a young man: case report. Clin Cases Miner Bone Metab 2013, 10:199-202.
5. Fraser L.A., Adachi J.D. Glucocorticoid-induced osteoporosis: treatment update and review. Ther Adv Musculoskelet Dis 2009, 1:71-85.
6. Manning L.I., Briggs A.M., Van Doornum S., Kale A., Kantor S., Wark J.D. Glucocorticoid-induced bone loss is associated with abnormal intravertebral areal bone mineral density distribution. Int J Endocrinol 2013, 2013:768579.
7. Lemaire V., Tobin F.L., Greller L.D., Cho C.R., Suva L.J. Modeling the interactions between osteoblast and osteoclast activities in bone remodeling. J Theor Biol 2004, 229:293-309.
8. Fumoto T., Takeshita S., Ito M., Ikeda K. Physiological functions of osteoblast lineage and T cell-derived RANKL in bone homeostasis. J Bone Miner Res 2014, 29:830-842.
9. Fakhry M., Hamade E., Badran B., Buchet R., Magne D. Molecular mechanisms of mesenchymal stem cell differentiation towards osteoblasts. World J Stem Cells 2013, 5:136-148.
10. Nakashima T. Regulation mechanism of bone remodeling. Kokubyo Gakkai Zasshi 2013, 80:75-80.
11. Tanaka Y. Glucocorticoid and bone metabolism and disease. Clin Calcium 2013, 23:229-235.
12. Mazziotti G., Giustina A., Canalis E., Bilezikian J.P. Treatment of glucocorticoid-induced osteoporsis. Ther Adv Musculoskelet Dis 2009, 1:27-34.
13. Couzin J. Genetics. Erasing microRNAs reveals their powerful punch. Science 2007, 316:530.
14. Zamore P.D., Haley B. Ribo-gnome: the big world of small RNAs. Science 2005, 309:1519-1524.
15. Zeng Y. Principles of micro-RNA production and maturation. Oncogene 2006, 25:6156-6162.
16. Kureel J., Dixit M., Tyagi A.M., Mansoori M.N., Srivastava K., Raghuvanshi A., et al. miR-542-3p suppresses osteoblast cell proliferation and differentiation, targets BMP-7 signaling and inhibits bone formation. Cell Death Dis 2014, 5:e1050.
17. Vimalraj S., Partridge N.C., Selvamurugan N. A positive role of microRNA-15b on regulation of osteoblast differentiation. J Cell Physiol 2014, 229:1236-1244.
18. Franceschetti T., Kessler C.B., Lee S.K., Delany A.M. miR-29 promotes murine osteoclastogenesis by regulating osteoclast commitment and migration. J Biol Chem 2013, 288:33347-33360.
19. Lee Y., Kim H.J., Park C.K., Kim Y.G., Lee H.J., Kim J.Y., et al. MicroRNA-124 regulates osteoclast differentiation. Bone 2013, 56:383-389.
20. Wang F.S., Chuang P.C., Lin C.L., Chen M.W., Ke H.J., Chang Y.H., et al. MicroRNA-29a protects against glucocorticoid-induced bone loss and fragility in rats by orchestrating bone acquisition and resorption. Arthritis Rheum 2013, 65:1530-1540.
21. Guo L., Xu J., Qi J., Zhang L., Wang J., Liang J., et al. MicroRNA-17-92a upregulation by estrogen leads to Bim targeting and inhibition of osteoblast apoptosis. J Cell Sci 2013, 126:978-988.
22. Wu X., McKenna M.A., Feng X., Nagy T.R., McDonald J.M. Osteoclast apoptosis: the role of Fas in vivo and in vitro. Endocrinology 2003, 144:5545-5555.
23. Itzstein C., van T H.R. Osteoclast formation in mouse co-cultures. Methods Mol Biol 2012, 816:177-186.
24. Gohel A., McCarthy M.B., Gronowicz G. Estrogen prevents glucocorticoid-induced apoptosis in osteoblasts in vivo and in vitro. Endocrinology 1999, 140:5339-5347.
25. Luo X., Xiao J., Lin H., Li B., Lu Y., Yang B., et al. Transcriptional activation by stimulating protein 1 and post-transcriptional repression by muscle-specific microRNAs of IKs-encoding genes and potential implications in regional heterogeneity of their expressions. J Cell Physiol 2007, 212:358-367.
26. Yang B., Lin H., Xiao J., Lu Y., Luo X., Li B., et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 2007, 13:486-491.
27. Feng S., Deng L., Chen W., Shao J., Xu G., Li Y.P. Atp6v1c1 is an essential component of the osteoclast proton pump and in F-actin ring formation in osteoclasts. Biochem J 2009, 417:195-203.
28. Takuma A., Kaneda T., Sato T., Ninomiya S., Kumegawa M., Hakeda Y. Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts. J Biol Chem 2003, 278:44667-44674.
29. Weinstein R.S., Jilka R.L., Parfitt A.M., Manolagas S.C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998, 102:274-282.
30. Shuto T., Kukita T., Hirata M., Jimi E., Koga T. Dexamethasone stimulates osteoclast-like cell formation by inhibiting granulocyte-macrophage colony-stimulating factor production in mouse bone marrow cultures. Endocrinology 1994, 134:1121-1126.
31. Dempster D.W., Moonga B.S., Stein L.S., Horbert W.R., Antakly T. Glucocorticoids inhibit bone resorption by isolated rat osteoclasts by enhancing apoptosis. J Endocrinol 1997, 154:397-406.
32. Kim H.J., Zhao H., Kitaura H., Bhattacharyya S., Brewer J.A., Muglia L.J., et al. Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 2006, 116:2152-2160.
33. Kaji H., Sugimoto T., Kanatani M., Nishiyama K., Chihara K. Dexamethasone stimulates osteoclast-like cell formation by directly acting on hemopoietic blast cells and enhances osteoclast-like cell formation stimulated by parathyroid hormone and prostaglandin E2. J Bone Miner Res 1997, 12:734-741.
34. Udagawa N., Takahashi N., Akatsu T., Sasaki T., Yamaguchi A., Kodama H., et al. The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology 1989, 125:1805-1813.
35. Furuya Y. Stimulation of bone formation in cortical bone of mice treated with a receptor activator of nuclear factor-kappaB ligand (RANKL)-binding peptide that possesses osteoclastogenesis inhibitory activity 2013, 288:5562-5571.
36. Mizoguchi F., Murakami Y., Saito T., Miyasaka N., Kohsaka H. miR-31 controls osteoclast formation and bone resorption by targeting RhoA. Arthritis Res Ther 2013, 15:R102.
37. Cheng P., Chen C., He H.B., Hu R., Zhou H.D., Xie H., et al. miR-148a regulates osteoclastogenesis by targeting V-maf musculoaponeurotic fibrosarcoma oncogene homolog B. J Bone Miner Res 2013, 28:1180-1190.
38. Kagiya T., Nakamura S. Expression profiling of microRNAs in RAW264.7 cells treated with a combination of tumor necrosis factor alpha and RANKL during osteoclast differentiation. J Periodontal Res 2013, 48:373-385.
39. Ikeda T., Kasai M., Utsuyama M., Hirokawa K. Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. Endocrinology 2001, 142:1419-1426.